An open study of tacrolimus therapy in Rasmussen encephalitis

CG Bien, U Gleissner, R Sassen, G Widman… - Neurology, 2004 - AAN Enterprises
CG Bien, U Gleissner, R Sassen, G Widman, H Urbach, CE Elger
Neurology, 2004AAN Enterprises
Seven patients with Rasmussen encephalitis (RE) were treated with the
immunosuppressant tacrolimus and followed for a median of 22.4 months. They were
compared with 12 historical untreated RE patients (median follow-up 13.9 months). The
tacrolimus-treated patients had a superior outcome regarding neurologic function and
progression rate of cerebral hemiatrophy but no better seizure outcome. No treated patient,
but 7 of 12 control patients, became eligible for hemispherectomy. Tacrolimus did not have …
Seven patients with Rasmussen encephalitis (RE) were treated with the immunosuppressant tacrolimus and followed for a median of 22.4 months. They were compared with 12 historical untreated RE patients (median follow-up 13.9 months). The tacrolimus-treated patients had a superior outcome regarding neurologic function and progression rate of cerebral hemiatrophy but no better seizure outcome. No treated patient, but 7 of 12 control patients, became eligible for hemispherectomy. Tacrolimus did not have any major side effects.
American Academy of Neurology